welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Sarepta Therapeutics Reports Sustained Functional Improvement Two Years After Treatment With SRP-9001, Its Investigational Micro-Dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, today announced two-year follow up results from four Duchenne muscular dystrophy (DMD) clinical trial participants who received SRP-9001 (AAVrh74.MHCK7.micro-dystrophin). SRP-9001 is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene to muscle tissue for the targeted production of micro-dystrophin protein. Results presented at the 25th International Annual Congress of the World Muscle Society demonstrated that two years after a one-time infusion of SRP-9001, trial participants exhibited a mean 7.0 point improvement on the North Star Ambulatory Assessment (NSAA) compared to baseline.
“We continue to be encouraged by the safety profile and enduring treatment response that we have seen to date with SRP-9001 gene transfer therapy,” said Doug Ingram, President and CEO, Sarepta.
rareRelated
-
Sarepta Therapeutics to Commence Dosing of the Next Study With Commercial Process Material for the SRP-9001 Gene The...Sarepta Therapeutics, Inc., the leader i...
-
A Randomized, Double-blind, Placebo-controlled Study of SRP-9001 for Duchenne Muscular Dystrophy (DMD)The purpose of this study is to evaluate...
-
A Gene Delivery Study to Evaluate the Safety of and Expression From SRP-9001 in Duchenne Muscular Dystrophy (DMD)This is an open-label gene delivery stud...
-
Treatment Effect of Tamoxifen on Patients With DMDDuchenne muscular dystrophy (DMD) is a p...
-
Capricor trial failure in heart disease might offer another opportunityOn Friday Capricor Therapeutics announce...
-
FibroGen Receives Fast Track Designation From the U.S. FDA for Pamrevlumab for the Treatment of Idiopathic Pulmonary...FibroGen, Inc., a biopharmaceutical comp...
-
A Phase 3 Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids, in Ambulatory Subj...To evaluate the efficacy and safety of p...
-
Capricor Therapeutics to Meet With FDA to Discuss CAP-1002 to Treat Duchenne Muscular DystrophyCapricor Therapeutics, a clinical-stage ...
-
First Patient Enrolled in Mallinckrodt’s Phase 2 Duchenne Muscular Dystrophy TrialMallinckrodt plc, a leading global spec...
